Latest 10-K annual reports

Ranger Energy Services, Inc. reported a 33% decline in net income for 2025, despite a strategic acquisition and growth in its High Specification Rigs segment.

Profound Medical Corp. reported a 51% increase in revenue for the year ended December 31, 2025, driven by strong TULSA-PRO sales, but also saw its net loss widen to $42.57 million.

NextCure, Inc. reported continued net losses and a going concern warning for 2025, while advancing its lead antibody-drug conjugate candidates and securing additional financing.

Gevo, Inc. announced a significant increase in 2025 revenues driven by its Red Trail Energy acquisition, while also substantially reducing its net loss, despite ongoing capital needs and an identified internal control weakness.

REGENXBIO reported increased revenues and a reduced net loss in 2025, driven by new partnerships, but faces significant regulatory setbacks for its MPS I and MPS II gene therapies and a going concern warning.

ContextLogic Holdings Inc. completed its strategic pivot by divesting Wish.com, reorganizing to preserve significant tax assets, and acquiring US Salt, a leading evaporated salt producer, signaling a new era as a business ownership platform.

Citizens Community Bancorp, Inc. announced increased net income and diluted earnings per share for fiscal year 2025, driven by higher net interest income and strategic balance sheet optimization.

Grove Collaborative Holdings, Inc. reports a 15% revenue decline and negative Adjusted EBITDA for 2025, alongside an ongoing NYSE delisting threat and a legal investigation into its auto-renewal practices.

Orion Properties Inc. reports a challenging 2025 with significant net losses and declining revenues, driven by persistent office market headwinds and substantial impairment charges, despite strategic shifts towards dedicated use assets and debt refinancing efforts.

ArriVent BioPharma, a clinical-stage biopharmaceutical company, reported significant operating losses for fiscal year 2025 while advancing its lead oncology candidates, firmonertinib and ARR-217, through pivotal clinical trials and strategic collaborations.

Phio Pharmaceuticals reports promising early clinical data for PH-762 and significant capital raises in 2025, extending its operational runway.

Ambiq Micro's 2025 annual report reveals a strategic shift to higher-margin edge AI markets, resulting in improved gross margins despite a slight dip in net sales and continued net losses.

Allient Inc. announced a significant increase in revenue, net income, and EPS for fiscal year 2025, driven by strategic initiatives and strong market demand.

Entravision Communications Corporation reported a 23% increase in consolidated net revenue for 2025, driven by strong growth in its Advertising Technology & Services segment, despite a decline in its traditional media business.

Lineage Cell Therapeutics, Inc. reported significant progress in its cell therapy pipeline and collaborations for 2025, alongside a substantial increase in net operating losses.

Weave Communications, Inc. announced its 2025 annual results, showcasing significant revenue growth and strategic advancements in AI-powered solutions for healthcare SMBs, despite continued net losses and a decline in retention rates.

Metagenomi Therapeutics, Inc. reported an increased net loss in 2025, alongside a strategic reprioritization of its pipeline, a 25% workforce reduction, and an extension of its cash runway into late 2027.

aTyr Pharma announced that its lead candidate, efzofitimod, failed to meet its primary endpoint in the Phase 3 EFZO-FIT study for pulmonary sarcoidosis, though secondary endpoints showed clinical improvements.

WEBTOON Entertainment Inc. reported a significant net loss for 2025, primarily driven by substantial goodwill impairment charges, despite revenue growth fueled by IP Adaptations.

Nutex Health Inc. reported significant revenue and net income growth in 2025, driven by its hospital division and successful navigation of the No Surprises Act's arbitration process, despite facing ongoing litigation and regulatory uncertainties.

ESS Tech, a long-duration energy storage company, reported a significant revenue decline and substantial doubt about its ability to continue as a going concern, despite ongoing capital raises and cost-cutting measures.

Wheeler Real Estate Investment Trust reports a net income increase in 2025, driven by property sales gains, but faces ongoing common stock dilution from preferred share redemptions and convertible notes.

Contineum Therapeutics, Inc. reported a net loss of $59.978 million for 2025, initiated a Phase 2 trial for PIPE-791 in IPF, and saw its partnered PIPE-307 fail its primary efficacy endpoints in RRMS.

Caribou Biosciences announced promising Phase 1 clinical trial results for its CAR-T cell therapies vispa-cel and CB-011, but faces significant operating losses and requires substantial additional financing for pivotal trials.

NCS Multistage Holdings, Inc. announced a significant increase in net income and revenue for fiscal year 2025, driven by strong product sales and a strategic acquisition, despite ongoing market volatility and a substantial tax reassessment.

TriSalus Life Sciences, Inc. reported a 53.4% increase in TriNav revenue for 2025, alongside continued development of its immuno-oncology therapeutic, nelitolimod, while navigating ongoing operating losses and internal control weaknesses.

Cedar Realty Trust, a REIT focused on grocery-anchored shopping centers, reported a net loss of $1.87 million for 2025, driven by property dispositions and impairment charges, despite strategic preferred stock repurchases.

CAMP4 Therapeutics reported a significant increase in net losses for 2025, reaching $80.4 million, while advancing its lead SYNGAP1 therapeutic and securing new funding and collaborations.

Evommune, a clinical-stage biotechnology company, reported positive Phase 2a results for EVO301 in atopic dermatitis and detailed its financial position following a November 2025 IPO and a February 2026 private placement.

Hawthorn Bancshares, Inc. announced a significant increase in net income and earnings per share for the fiscal year ended December 31, 2025, driven by improved net interest income and efficiency.